Next Article in Journal
Advanced Glycation End-Products (AGEs): Formation, Chemistry, Classification, Receptors, and Diseases Related to AGEs
Next Article in Special Issue
Secretory Immunoglobulin A Immunity in Chronic Obstructive Respiratory Diseases
Previous Article in Journal
Selectin-Mediated Signaling—Shedding Light on the Regulation of Integrin Activity in Neutrophils
Previous Article in Special Issue
Extracellular Lipids in the Lung and Their Role in Pulmonary Fibrosis
 
 
Article

Salvia miltiorrhiza Bunge as a Potential Natural Compound against COVID-19

1
Louvain Institute of Biomolecular Science and Technology, Université Catholique de Louvain, 1348 Louvain-la-Neuve, Belgium
2
Pole of Pneumology, ENT and Dermatology, Institute of Experimental and Clinical Research (IREC), Université Catholique de Louvain, 1348 Brussels, Belgium
3
BOTALYS, 8 Avenue des Artisans, 7822 Ghislenghien, Belgium
4
Walloon Excellence in Life Sciences and Biotechnology (WELBIO), 1300 Wavre, Belgium
5
Department of Pneumology, Cliniques Universitaires Saint-Luc, 1200 Brussels, Belgium
*
Author to whom correspondence should be addressed.
Academic Editor: Mauro Maniscalco
Cells 2022, 11(8), 1311; https://doi.org/10.3390/cells11081311
Received: 11 March 2022 / Revised: 1 April 2022 / Accepted: 6 April 2022 / Published: 12 April 2022
(This article belongs to the Special Issue Mucosal Immunity in Respiratory Diseases Ⅱ)
Salvia miltiorrhiza Bunge, commonly called danshen, is widely used in traditional Chinese medicine for its cardiovascular and neuroprotective effects, which include antioxidative, anti-inflammatory, and antifibrotic properties. The purpose of this study was to evaluate the preclinical potential of S. miltiorrhiza extracts for the treatment of COVID-19. First, the impact of the extract on the binding between SARS-CoV-2 and the cellular ACE2 receptors was assessed using atomic force microscopy (AFM), showing a significant reduction in binding by the extract at concentrations in the µg/mL range. Second, the interference of this extract with the inflammatory response of blood mononuclear cells (PBMCs) was determined, demonstrating potent inhibitory properties in the same concentration range on pro-inflammatory cytokine release and interference with the activation of NFκB signaling. Together, these in vitro data demonstrate the potential of S. miltiorrhiza against COVID-19, consisting first of the blockade of the binding of SARS-CoV-2 to the ACE2 receptor and the mitigation of the inflammatory response from leukocytes by interfering with NFκB signaling. This dataset prompts the launch of a clinical trial to address in vivo the clinical benefits of this promising agent. View Full-Text
Keywords: SARS-CoV-2; COVID-19; ACE2; infection; viral entry; binding inhibitor; AFM; atomic force microscopy; force spectroscopy; single-molecule SARS-CoV-2; COVID-19; ACE2; infection; viral entry; binding inhibitor; AFM; atomic force microscopy; force spectroscopy; single-molecule
Show Figures

Figure 1

MDPI and ACS Style

Petitjean, S.J.L.; Lecocq, M.; Lelong, C.; Denis, R.; Defrère, S.; Mariage, P.-A.; Alsteens, D.; Pilette, C. Salvia miltiorrhiza Bunge as a Potential Natural Compound against COVID-19. Cells 2022, 11, 1311. https://doi.org/10.3390/cells11081311

AMA Style

Petitjean SJL, Lecocq M, Lelong C, Denis R, Defrère S, Mariage P-A, Alsteens D, Pilette C. Salvia miltiorrhiza Bunge as a Potential Natural Compound against COVID-19. Cells. 2022; 11(8):1311. https://doi.org/10.3390/cells11081311

Chicago/Turabian Style

Petitjean, Simon J. L., Marylène Lecocq, Camille Lelong, Robin Denis, Sylvie Defrère, Pierre-Antoine Mariage, David Alsteens, and Charles Pilette. 2022. "Salvia miltiorrhiza Bunge as a Potential Natural Compound against COVID-19" Cells 11, no. 8: 1311. https://doi.org/10.3390/cells11081311

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop